Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 305-310

  Avitabile, Nicholas ^a   Banka, Ajaz ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A1C; bile acid sequestrants; HDL C; LDL C; triglycerides; type 2 diabetes mellitus

Indexed keywords

ANTIARRHYTHMIC AGENT; COLESEVELAM; EZETIMIBE; INSULIN; LEVOTHYROXINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; WARFARIN;

ASTHENIA; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; ESOPHAGUS OBSTRUCTION; FLATULENCE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; LIPID BLOOD LEVEL; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; WEAKNESS;

ADULT; ALLYLAMINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952339105     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.548320     Document Type: Review

References (13)

1. Steinmetz K. Colesevelam hydrochloride. Am J Health-Syst Pharm 2002;59:932-9 (Pubitemid 34522595)
2. Product information. Welchol (Colesevelam hydrochloride) Parsippany, Daiichi Sankyo Inc., NJ; 2009
3. Brunetti L, Hermes-DeSantis ER. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother 2010;44:1196-206
4. Holmes-Farley SR, Manderville WH, Miller KL, et al. Colesevelam hydrochloride: synthesis and testing of a novel polymer gel pharmaceutical. Polym Preprints 2000;41:735-6
5. Hanus M, Zhorov E. Bile acid salt binding with colesevelam is not affected after suspension in common beverages. J Pharm Sci 2006;95:2751-9 (Pubitemid 46093181)
6. Davidson M, Hunninghake D, Olson T, et al. Colesevelam HCl (WelcholTM), a new, potent, well tolerated, non systemic, lipid lowering agent. Paper presented at 12th international Symposium on Atherosclerosis. Stockholm, Sweden; 2000
7. Insull W, Toth P, Mullican W, et al. Cholestagel, a novel, highly potent, polymeric bile acid sequestrant significantly lowers LDL cholesterol (Abstract). J Am Coll Cardiol 2000;35:258A
8. Braunlin W, Zhorov E, Smisek D, et al. Invitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polym Preprints 2000;41:708-9
9. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
10. Rosenstock J, Fonseca VA. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 2010;16:629-40
11. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reducesLDLcholesterol inpatients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84
12. Goldfine AB, Fonseca VA, Jones MR, editors. Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes. Horm Metab Res 2010;42(1):23-30
13. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900 (Pubitemid 29424709)